CurrentEndo coverage · page 53 of 55

Diabetes, Obesity and Metabolism

Briefs 2,081–2,120 of 2,200 CurrentEndo has covered from this journal, newest publication first

Latest from Diabetes, Obesity and Metabolism

All coverage, newest first

Diabetes Obes Metab28 Feb 2023
iGlarLixi versus premixed insulin initiation in adults with type 2 diabetes advancing from basal insulin therapy: The SoliComplex real‐world study
Cohort studyT2D & other
Diabetes Obes Metab28 Feb 2023
Improvement of glycaemic control and treatment satisfaction by switching from liraglutide or dulaglutide to subcutaneous semaglutide in patients with type 2 diabetes: A multicentre, prospective, randomized, open‐label, parallel‐group comparison study ( SWITCH‐SEMA 1 study)
Randomized controlled trialT2D & other
Diabetes Obes Metab26 Feb 2023
Effects of finerenone in people with chronic kidney disease and type 2 diabetes are independent of HbA1c at baseline, HbA1c variability, diabetes duration and insulin use at baseline
Secondary analysisT2D & other
Diabetes Obes Metab22 Feb 2023
Comparative efficacy of sodium‐glucose co‐transporter‐2 inhibitors, glucagon‐like peptide‐1 receptor agonists and non‐steroidal mineralocorticoid receptor antagonists in chronic kidney disease and type 2 diabetes: A systematic review and network meta‐analysis
Meta-analysisT2D & other
Diabetes Obes Metab22 Feb 2023
Effects of co‐ingesting glucose and whey protein on blood glucose, plasma insulin and glucagon concentrations, and gastric emptying, in older men with and without type 2 diabetes
Mechanistic studyT2D & other
Diabetes Obes Metab21 Feb 2023
Empagliflozin versus sitagliptin for ameliorating intrahepatic lipid content and tissue‐specific insulin sensitivity in patients with early‐stage type 2 diabetes with non‐alcoholic fatty liver disease: A prospective randomized study
Randomized controlled trialT2D & other
Diabetes Obes Metab21 Feb 2023
One‐year real‐world performance of the DBLG1 closed‐loop system: Data from 3706 adult users with type 1 diabetes in Germany
Cohort studyTechnology
Diabetes Obes Metab21 Feb 2023
Safety and tolerability of semaglutide across the SUSTAIN and PIONEER phase IIIa clinical trial programmes
Meta-analysisT2D & other
Diabetes Obes Metab20 Feb 2023
Glucagon‐like peptide 1 receptor agonists in patients with type 2 diabetes with and without chronic heart failure: A meta‐analysis of randomized placebo‐controlled outcome trials
Meta-analysisT2D & other
Diabetes Obes Metab20 Feb 2023
Long‐term cost‐effectiveness analysis of tirzepatide versus semaglutide 1.0 mg for the management of type 2 diabetes in the United States
Research articleT2D & other
Diabetes Obes Metab20 Feb 2023
Sustained heart rate‐corrected QT prolongation during recovery from hypoglycaemia in people with type 1 diabetes, independently of recovery to hyperglycaemia or euglycaemia
Randomized controlled trialT1D
Diabetes Obes Metab16 Feb 2023
Sulphonylureas versus metformin and the risk of ventricular arrhythmias among people with type 2 diabetes: A population‐based cohort study
Cohort studyT2D & other
Diabetes Obes Metab14 Feb 2023
Impact of baseline kidney function on the effects of sodium‐glucose co‐transporter‐2 inhibitors on kidney and heart failure outcomes: A systematic review and meta‐analysis of randomized controlled trials
Meta-analysisT2D & other
Diabetes Obes Metab14 Feb 2023
Incident and recurrent hypoglycaemia with linagliptin and glimepiride over a median of 6 years in the CAROLINA cardiovascular outcome trial
Secondary analysisT2D & other
Diabetes Obes Metab14 Feb 2023
Integrated safety and efficacy analysis of dasiglucagon for the treatment of severe hypoglycaemia in individuals with type 1 diabetes
Secondary analysisT1D
Diabetes Obes Metab14 Feb 2023
Long‐term impact of weight loss for people with overweight but not obesity, and with type 2 diabetes: 10‐year outcomes of a randomized trial of gastric band surgery
Randomized controlled trialObesity
Diabetes Obes Metab14 Feb 2023
Pharmacokinetic and pharmacodynamic equivalence of Biocon's biosimilar insulin N with US ‐licensed Humulin® N formulation in healthy subjects: Results from the RHINE ‐2 (Recombinant Human INsulin Equivalence‐2) study
Randomized controlled trialT2D & other
Diabetes Obes Metab14 Feb 2023
Professional continuous glucose monitoring in patients with diabetes mellitus: A systematic review and meta‐analysis
Meta-analysisTechnology
Diabetes Obes Metab14 Feb 2023
Pyridoxamine reduces methylglyoxal and markers of glycation and endothelial dysfunction, but does not improve insulin sensitivity or vascular function in abdominally obese individuals: A randomized double‐blind placebo‐controlled trial
Randomized controlled trialObesity
Diabetes Obes Metab14 Feb 2023
Sex differences in the complications, care and clinical outcomes of patients with type 2 diabetes in the Exenatide Study of Cardiovascular Event Lowering ( EXSCEL )
Secondary analysisT2D & other
Diabetes Obes Metab10 Feb 2023
Identifying diabetogenic drugs using real world health care databases: A Danish and Australian symmetry analysis
Cohort studyT2D & other
Diabetes Obes Metab10 Feb 2023
Therapeutic inertia related to the injectable glucagon‐like peptide‐1 receptor agonists dulaglutide and semaglutide in patients with type 2 diabetes in UK primary care
Cohort studyT2D & other
Diabetes Obes Metab8 Feb 2023
Meta‐analysis of head‐to‐head clinical trials comparing incretin‐based glucose‐lowering medications and basal insulin: An update including recently developed glucagon‐like peptide‐1 ( GLP ‐1) receptor agonists and the glucose‐dependent insulinotropic polypeptide/ GLP ‐1 receptor co‐agonist tirzepatide
Meta-analysisT2D & other
Diabetes Obes Metab2 Feb 2023
Effects of sodium‐glucose cotransporter 2 inhibitors, mineralocorticoid receptor antagonists, and their combination on albuminuria in diabetic patients
Meta-analysisT2D & other
Diabetes Obes Metab1 Feb 2023
Joint longitudinal and time‐to‐event modelling compared with standard Cox modelling in patients with type 2 diabetes with and without established cardiovascular disease: An analysis of the EXSCEL trial
Secondary analysisT2D & other
Diabetes Obes Metab31 Jan 2023
A co‐formulation of pramlintide and insulin A21G ( ADO09 ) improves postprandial glucose and short‐term control of mean glucose, time in range, and body weight versus insulin aspart in adults with type 1 diabetes
Randomized controlled trialT1D
Diabetes Obes Metab30 Jan 2023
Phase I studies of the safety, tolerability, pharmacokinetics and pharmacodynamics of the dual glucagon receptor/glucagon‐like peptide‐1 receptor agonist BI 456906
Randomized controlled trialObesity
Diabetes Obes Metab23 Jan 2023
Investigating the potential non‐authorized use of two different formulations of liraglutide in Europe: A real‐world drug utilization study
Cohort studyT2D & other
Diabetes Obes Metab23 Jan 2023
A microbiome‐targeting fibre‐enriched nutritional formula is well tolerated and improves quality of life and haemoglobin A1c in type 2 diabetes: A double‐blind , randomized, placebo‐controlled trial
Randomized controlled trialT2D & other
Diabetes Obes Metab20 Jan 2023
Efficacy and safety of janagliflozin monotherapy in Chinese patients with type 2 diabetes mellitus inadequately controlled on diet and exercise: A multicentre, randomized, double‐blind, placebo‐controlled, Phase 3 trial
Randomized controlled trialT2D & other
Diabetes Obes Metab20 Jan 2023
Safety and efficacy analyses across age and body mass index subgroups in East Asian participants with type 2 diabetes in the phase 3 tirzepatide studies ( SURPASS programme)
Secondary analysisT2D & other
Diabetes Obes Metab19 Jan 2023
Efficacy and safety of basal‐first titration order in individuals with type 2 diabetes receiving short‐term intensive insulin therapy: An exploratory analysis of BEYOND V
Secondary analysisT2D & other
Diabetes Obes Metab19 Jan 2023
Exercise‐related hypoglycaemia induces QTc ‐interval prolongation in individuals with type 1 diabetes
Randomized controlled trialT1D
Diabetes Obes Metab19 Jan 2023
Liver‐expressed antimicrobial peptide 2 is associated with improved pancreatic insulin secretion in adults with overweight and obesity
Cross-sectional studyObesity
Diabetes Obes Metab17 Jan 2023
Lifestyle intervention for the prevention of type 2 diabetes in women with prior gestational diabetes: A systematic review and meta‐analysis
Meta-analysisDiabetes in pregnancy
Diabetes Obes Metab17 Jan 2023
A phase 2a, randomized, double‐blind, placebo‐controlled, three‐arm, parallel‐group study to assess the efficacy, safety, tolerability and pharmacodynamics of PF ‐06835919 in patients with non‐alcoholic fatty liver disease and type 2 diabetes
Randomized controlled trialT2D & other
Diabetes Obes Metab11 Jan 2023
IMpact of flash glucose Monitoring in pEople with type 2 Diabetes Inadequately controlled with non‐insulin Antihyperglycaemic ThErapy ( IMMEDIATE ): A randomized controlled trial
Randomized controlled trialT2D & other
Diabetes Obes Metab10 Jan 2023
Anagliptin twice‐daily regimen improves glycaemic variability in subjects with type 2 diabetes: A d ouble‐blind , randomized controlled trial
Randomized controlled trialT2D & other
Diabetes Obes Metab10 Jan 2023
Association of long‐term hyperglycaemia and insulin resistance with brain atrophy and cognitive decline: A longitudinal cohort study
Cohort studyT2D & other
Diabetes Obes Metab9 Jan 2023
Pharmacokinetic and pharmacodynamic properties of the novel basal insulin Fc (insulin efsitora alfa), an insulin fusion protein in development for once‐weekly dosing for the treatment of patients with diabetes
Research articleT2D & other

All 2,200 Briefs in ExploreShowing Briefs 2,081–2,120 of 2,200, newest first